New combo aims to shrink melanoma tumors before surgery
Disease control
Not yet recruiting
This study tests whether adding an experimental drug (PRTX007) to an approved immunotherapy (pembrolizumab) before surgery can improve outcomes for people with stage III melanoma. About 48 adults with resectable melanoma will receive the combination orally and intravenously, then…
Phase: PHASE2 • Sponsor: Primmune Therapeutics, Inc. • Aim: Disease control
Last updated May 12, 2026 13:39 UTC